Prognostic value of dynamic MR imaging for non‐small‐cell lung cancer patients after chemoradiotherapy

To determine the prognostic value of dynamic MRI for non‐small‐cell lung cancer (NSCLC) patients after chemoradiotherapy.

[1]  S. Graziano.  Non-small cell lung cancer: clinical value of new biological predictors , 1997 .

[2]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[3]  W E Reddick,et al.  Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma , 1999, Journal of magnetic resonance imaging : JMRI.

[4]  M. Kusumoto,et al.  Gadopentetate-dimeglumine-enhanced magnetic resonance imaging for lung nodules. Differentiation of lung cancer and tuberculoma. , 1994, Investigative radiology.

[5]  R Collins,et al.  Blood flow in the lung. , 1979, Journal of biomechanics.

[6]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[7]  J C Ehrhardt,et al.  Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. , 1996, International journal of radiation oncology, biology, physics.

[8]  R R Edelman,et al.  Pulmonary perfusion: Qualitative assessment with dynamic contrast‐enhanced MRI using ultra‐short TE and inversion recovery turbo FLASH , 1996, Magnetic resonance in medicine.

[9]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[10]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[11]  K. Deppermann.  Influence of age and comorbidities on the chemotherapeutic management of lung cancer. , 2001, Lung cancer.

[12]  Hiroto Hatabu,et al.  Solitary pulmonary nodules: potential role of dynamic MR imaging in management initial experience. , 2002, Radiology.

[13]  R. Paola,et al.  Correlation Between Contrast Enhancement in Dynamic Magnetic Resonance Imaging of the Breast and Tumor Angiogenesis , 1994, Investigative radiology.

[14]  W. Steinbrich,et al.  Solitary pulmonary nodules: MR evaluation of enhancement patterns with contrast-enhanced dynamic snapshot gradient-echo imaging. , 1996, Radiology.

[15]  J. T. Littleton,et al.  Pulmonary masses: contrast enhancement. , 1990, Radiology.

[16]  P. Price.  Atlas of Clinical PET in Oncology , 2000, British Journal of Cancer.

[17]  T. Mitsudomi,et al.  Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. , 1997, The Annals of thoracic surgery.

[18]  R R Edelman,et al.  Evaluation of regional pulmonary perfusion using ultrafast magnetic resonance imaging , 2001, Magnetic resonance in medicine.

[19]  Y. Koh,et al.  Characteristics of lung cancer in Korea, 1997. , 2000, Lung cancer.

[20]  M Kormano,et al.  Comparative Pharmacokinetics of Gadolinium DTPA and Gadolinium Chloride , 1988, Investigative radiology.

[21]  Didier Revel,et al.  Canine acute myocardial infarction. In vivo detection by MRI with gradient echo technique and contribution of Gd-DOTA. , 1988 .

[22]  Harvey I. Pass,et al.  Lung cancer : principles and practice , 1996 .

[23]  V Kalff,et al.  The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Fischman,et al.  Dynamic T1-weighted magnetic resonance imaging and positron emission tomography in patients with lung cancer: correlating vascular physiology with glucose metabolism. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  N. Niles.  Pathologic Basis of Disease , 1974 .

[26]  A. Berger.  FUNDAMENTALS OF BIOSTATISTICS , 1969 .

[27]  John E. Connolly,et al.  Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.

[28]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[29]  Yukiko Arisaka,et al.  18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[31]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.

[32]  N Zamboglou,et al.  Predictive factors in radiotherapy for non-small cell lung cancer: present status. , 2001, Lung cancer.

[33]  M. Kusumoto,et al.  Predicting the prognosis of non-small cell lung cancer patient treated with conservative therapy using contrast-enhanced MR imaging , 2000, European Radiology.

[34]  J. Izbicki,et al.  Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. , 1996, The Annals of thoracic surgery.

[35]  R R Edelman,et al.  Quantitative assessment of pulmonary perfusion with dynamic contrast‐enhanced MRI , 1999, Magnetic resonance in medicine.

[36]  W. Reddick,et al.  Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors , 2001, Pediatric Radiology.